Chronic Kidney Disease
Conditions
Keywords
Chronic kidney disease, Diabetes nephropathy, Drug effectiveness, Drug safety, Drug economics
Brief summary
Chronic kidney disease (CKD), characterized as renal dysfunction, is recognized as a major public health problem with high morbidity and mortality worldwide. This study aimed to analyze the common drug use and combinations of different stages and types of CKD patients. The study is a multicenter retrospective study involving three hospitals. Investigators reviewed and analyzed all patients diagnosed with chronic kidney disease from July 1, 2020 to June 30, 2022. Chronic kidney disease was defined as eGFR less than 60 mL/min per 1·73 m(2) or the presence of albuminuria. The study selected seven types of drugs based on hospital electronic medical record data, including β Receptor blockers, angiotensin converting enzyme inhibitor blockers, angiotensin II receptors, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, and calcium channel blockers. Chi-square test, Mann-Whitney Wilcoxon test, and Kruskal Wallis test will be used for statistical analysis. The main purpose of this study is to provide evidence for promoting rational drug use in CKD patients by describing the drug use. The secondary purpose of the study is to explore the efficacy, safety and economy of SGLT-2 inhibitors in diabetes nephropathy (DN).
Interventions
DRUGangiotensin converting enzyme inhibitors, angiotensin II receptor blockers, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, calcium channel blockers, β Receptor blocker
Drug types: angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, calcium channel blockers, β Receptor blockers Treatment prescription: medication alone or in combination Dose used: \<standard dose, standard dose, \>standard dose Frequency of administration: once a day, twice a day, three times a day.
Sponsors
Qianfoshan Hospital
Study design
Observational model
OTHER
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Visit time (based on admission time for inpatients) is from July 1, 2020 to June 30, 2022 2. Any diagnostic type of the patient's visit includes CKD related diagnostics 3. Age ≥ 18 years old
Exclusion criteria
1. Diagnosis includes malignant tumors 2. Diagnosis includes uremia, hemodialysis, or peritoneal dialysis 3. Diagnosis includes jaundice 4. Incomplete clinical data
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| eGFR | October , 2023 | The current treatment status and medication regimen of CKD patients with different risk stratification were analyzed by GFR staging. |
| albuminuria | October , 2023 | The current treatment status and medication regimen of CKD patients with different risk stratification were analyzed by albuminuria grading. |
Countries
China
Outcome results
None listed